You finish dinner, put the dishes away, and realize you’re still hungry.

If that feels familiar, the frustrating part may be what happens next: mentally reviewing everything you ate, wondering whether you should have chosen something different, promising to be stricter tomorrow. Especially if you’ve already spent months trying to manage your weight with PCOS.

Another explanation of healthy eating may not be the thing you’re missing. You may need a better conversation about why the current plan is so difficult to live with, and what treatment could make it more manageable.

That conversation can include peptide-based medicines such as GLP-1 receptor agonists. For some adults with PCOS who meet criteria for weight-management medication, they are a legitimate clinical option. The hopeful part is that care can address appetite and weight regulation directly, instead of simply asking for more restraint.

But persistent hunger does not identify its own cause. And a medicine that helps with weight is not automatically a treatment for every part of PCOS.

Insulin resistance matters. It isn’t the whole explanation.

PCOS insulin resistance is an important part of this conversation. Insulin helps the body use glucose; insulin resistance means tissues do not respond to it as well as they should. It can contribute to higher blood glucose. Yet insulin resistance and prediabetes usually have no obvious symptoms, according to the National Institute of Diabetes and Digestive and Kidney Diseases.

Feeling hungry cannot tell you whether you have insulin resistance, how severe it is, or which treatment would help.

The 2023 international PCOS guideline recognizes insulin resistance as part of PCOS biology, but advises against routine insulin assays because of their limited clinical usefulness. It recommends an oral glucose tolerance test as the most accurate assessment of blood-glucose status in PCOS, regardless of BMI. That assesses how the body handles glucose; it is not a test that explains every craving.

The distinction matters. An assessment can uncover a metabolic issue worth treating without reducing your whole experience to an insulin number.

Sometimes the plan deserves scrutiny, too

There is another question worth asking before making a food plan stricter: does it provide enough nourishment, and can you actually sustain it?

That is not an accusation that you’re eating incorrectly. It is permission to examine the plan with the same seriousness usually directed at your effort.

Hunger can also change after weight loss. In a 2011 human study, researchers enrolled 50 adults with overweight or obesity in a weight-loss program. Increased hunger and changes in several appetite-related hormones were still present a year after the initial weight loss. This was not a PCOS study, and it used a very-low-energy diet, so it cannot explain everyone’s experience. It does show why renewed hunger need not mean someone has suddenly stopped caring.

For PCOS specifically, the international guideline advises against unduly restrictive, nutritionally unbalanced diets. It finds no evidence that one dietary composition is best across the relevant health outcomes. It also recommends considering disordered eating at any weight, especially during weight-management care.

A clinician or dietitian can help distinguish persistent hunger from a pattern of restriction and loss-of-control eating, or recognize when both need attention. The answer should not automatically be another rule about what you are allowed to eat.

And support should not depend on achieving a smaller body. The guideline explicitly recognizes weight stigma and the benefits of healthy habits even without weight loss.

Where GLP-1 medicines offer a real opening

GLP-1 is a peptide hormone involved in appetite and glucose regulation. Medicines such as liraglutide and semaglutide activate its receptor. The current Wegovy prescribing information describes semaglutide as reducing calorie intake, with effects likely mediated through appetite.

This gives clinicians a way to work with appetite biology. Reducing appetite can be a legitimate treatment goal for an appropriate patient, rather than a test of character.

The PCOS guideline says anti-obesity medications, including liraglutide and semaglutide, could be considered for higher weight in adults with PCOS, alongside active lifestyle support and according to general-population guidelines. This is a conditional clinical option, not a recommendation that everyone with PCOS take one.

It is also different from saying these drugs are approved specifically for PCOS. For example, a person with PCOS may qualify for Wegovy under its weight-management indication. Prescribing a medicine specifically to treat PCOS is a separate, off-label question. The diagnosis alone does not establish eligibility.

Our semaglutide guide explains why the product and its approved use matter.

What has actually been shown in people with PCOS?

There is encouraging direct evidence, although it is smaller and less certain than the broader obesity evidence.

In a 2022 randomized, placebo-controlled trial, 82 women with PCOS and obesity were assigned to liraglutide or placebo, with lifestyle intervention in both groups. At 32 weeks, average weight reduction was 5.7% with liraglutide versus 1.4% with placebo. Gastrointestinal events were more common with liraglutide. Those results support a possible weight-management benefit; they do not establish permanent results or prove relief of persistent hunger specifically.

A 2025 randomized, open-label trial offers a newer semaglutide signal. It compared metformin plus semaglutide with metformin alone in women with PCOS and overweight or obesity. Of 100 randomized participants, 80 completed the study. After 16 weeks, reported average weight loss was 6.09 kilograms in the combination group versus 2.25 kilograms with metformin alone. This was a short study without blinding, and it tested adding semaglutide, not semaglutide by itself.

The broader picture remains cautious. A 2026 systematic review of 11 randomized trials found a modest short-term BMI benefit with low-certainty evidence. It could not establish reliable wider benefits across PCOS outcomes. Its search ended in September 2024, and its included trials tested neither semaglutide nor tirzepatide, so it does not settle the newer-drug question.

Tirzepatide acts on both GIP and GLP-1 receptors. Recent observational research includes women with self-reported PCOS, but it is not randomized evidence that tirzepatide treats PCOS itself.

The useful takeaway is hopeful and specific: medication may help some people manage weight. We still need better PCOS-specific evidence about hunger, long-term health, and reproductive outcomes.

What a more helpful next chapter could look like

These are possible care pathways, not patient stories or promised outcomes.

When weight-management medication fits

An adult with PCOS has persistent appetite concerns, meets criteria for an approved weight-management medicine, and wants to discuss treatment. Their clinician reviews glucose status, medical history, current medicines, eating patterns, and pregnancy plans before deciding whether a GLP-1 medicine is appropriate.

If it is, the plan can include the medicine alongside nutrition support and sustainable activity. Follow-up can ask whether hunger is becoming easier to manage, whether eating remains adequate, how side effects affect daily life, and whether the agreed health goals are being met.

That is a genuinely different proposition from being sent home with instructions to try harder. There is a treatment to evaluate, support around it, and room to change course if the balance of benefit and burden is wrong.

When metabolic care points somewhere else

Another adult’s assessment may lead to a discussion of metformin rather than an appetite-focused medicine. The PCOS guideline supports considering metformin for metabolic outcomes in appropriate adults, with recommendations that vary by BMI and clinical circumstances.

Metformin is not a peptide medicine. It belongs in this conversation because good care follows the person’s needs, not the category of treatment that attracted attention first. It should not be presented as a guaranteed fix for hunger either.

When the priority is repairing the relationship with food

If assessment identifies under-fueling, disordered eating, or an eating disorder, a more restrictive plan may be the wrong direction. Nutrition and psychological support can become central to care. The PCOS guideline supports assessment and appropriate treatment rather than assuming body size tells the whole story.

A person who does not qualify for a GLP-1 medicine, cannot tolerate one, or simply does not want one still deserves active treatment and follow-up.

A hopeful plan needs some practical guardrails

GLP-1 medicines have real trade-offs. Nausea, vomiting, diarrhea, and constipation can be troublesome. The current Wegovy label also includes warnings about pancreatitis, gallbladder problems, dehydration-related kidney injury, and severe gastrointestinal reactions. It is not recommended with severe gastroparesis and is contraindicated with a personal or family history of medullary thyroid carcinoma or MEN2. These are examples, not a complete safety checklist.

Pregnancy planning belongs near the start of the discussion. GLP-1 medicines used for weight management are not a pregnancy weight-loss strategy, and the PCOS guideline calls for effective contraception when pregnancy is possible. The Wegovy label specifies stopping at least two months before a planned pregnancy for weight-management use. The Zepbound label has a separate warning that tirzepatide can reduce oral hormonal contraceptive effectiveness, requiring discussion of a non-oral or additional barrier method during specified periods. The prescriber should make the medication-specific plan clear.

Long-term access matters, too. The guideline recommends discussing the potential need for ongoing treatment and the risk of weight regain after stopping. Cost, coverage, tolerability, and follow-up are part of whether a treatment is workable.

Success should also leave room for adequate nutrition and physical function. Our GLP-1 body-composition article explains why weight change and strength are different outcomes.

None of this evidence turns a research-use-only vial into a treatment option. The FDA warns against products falsely marketed for research or not for human consumption. Compounded drugs are also not FDA-approved; they should not be assumed equivalent to an approved product.

You can ask for more than another lifestyle lecture

A useful starting point for an appointment might be:

“I’ve made repeated changes, but hunger and weight concerns are still affecting my life. Can we review what might be contributing, check my metabolic health, and discuss whether medication or a different kind of support fits my goals?”

That question leaves room for several answers, including a GLP-1 medicine. It also makes your daily experience part of the decision, rather than treating the scale as the entire problem.

The hopeful ending isn’t that everyone with PCOS needs a peptide. It’s that there are evidence-supported options beyond repeating the same advice, and a good care plan can take both your biology and your effort seriously.

Educational reporting, not a diagnosis or an individualized treatment recommendation. Medication decisions require a qualified clinician who knows your history.